CU20200103A7 - Péptido sintético para la inducción de inmunidad antitumoral y antiviral - Google Patents
Péptido sintético para la inducción de inmunidad antitumoral y antiviralInfo
- Publication number
- CU20200103A7 CU20200103A7 CU2020000103A CU20200103A CU20200103A7 CU 20200103 A7 CU20200103 A7 CU 20200103A7 CU 2020000103 A CU2020000103 A CU 2020000103A CU 20200103 A CU20200103 A CU 20200103A CU 20200103 A7 CU20200103 A7 CU 20200103A7
- Authority
- CU
- Cuba
- Prior art keywords
- induction
- synthetic peptide
- tumor
- viral immunity
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 230000036039 immunity Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Abstract
<p>Péptido sintético para la inducción de inmunidad antitumoral y antiviral que se caracteriza porque posee una secuencia de aminoácidos identificada como SEQ ID No:1. Es también parte de la invención una combinación farmacéutica que comprende el péptido identificado como SEQ ID No. 1 y una vacuna para la inmunoterapia del cáncer, la que logra un abordaje inmunoterapéutico más efectivo de esta enfermedad.</p>
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000103A CU20200103A7 (es) | 2020-12-18 | 2020-12-18 | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
US18/268,118 US20240082392A1 (en) | 2020-12-18 | 2021-11-23 | Use of synthetic peptide for the induction of antitumor and antiviral immunity |
CA3201752A CA3201752A1 (en) | 2020-12-18 | 2021-11-23 | Use of synthetic peptide for the induction of antitumor and antiviral immunty |
BR112023011605A BR112023011605A2 (pt) | 2020-12-18 | 2021-11-23 | Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica |
EP21865362.4A EP4265268A2 (en) | 2020-12-18 | 2021-11-23 | Cigb-300 for use in the the induction of antitumor and antiviral immunty |
MX2023007293A MX2023007293A (es) | 2020-12-18 | 2021-11-23 | Uso de peptido sintetico para la induccion de inmunidad antitumoral y antiviral. |
JP2023536436A JP2023554401A (ja) | 2020-12-18 | 2021-11-23 | 合成ペプチドの、抗腫瘍及び抗ウイルス免疫の誘導のための使用 |
AU2021403339A AU2021403339A1 (en) | 2020-12-18 | 2021-11-23 | Use of synthetic peptide for the induction of antitumor and antiviral immunity |
CN202180093881.4A CN116963758A (zh) | 2020-12-18 | 2021-11-23 | 用于在诱导抗肿瘤和抗病毒免疫中使用的cigb-300 |
PCT/CU2021/050013 WO2022127945A2 (es) | 2020-12-18 | 2021-11-23 | Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral |
KR1020237023660A KR20230122063A (ko) | 2020-12-18 | 2021-11-23 | 항종양 및 항바이러스 면역 유도를 위한 합성 펩티드의용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020000103A CU20200103A7 (es) | 2020-12-18 | 2020-12-18 | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20200103A7 true CU20200103A7 (es) | 2022-07-08 |
Family
ID=80683707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2020000103A CU20200103A7 (es) | 2020-12-18 | 2020-12-18 | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240082392A1 (es) |
EP (1) | EP4265268A2 (es) |
JP (1) | JP2023554401A (es) |
KR (1) | KR20230122063A (es) |
CN (1) | CN116963758A (es) |
AU (1) | AU2021403339A1 (es) |
BR (1) | BR112023011605A2 (es) |
CA (1) | CA3201752A1 (es) |
CU (1) | CU20200103A7 (es) |
MX (1) | MX2023007293A (es) |
WO (1) | WO2022127945A2 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2020
- 2020-12-18 CU CU2020000103A patent/CU20200103A7/es unknown
-
2021
- 2021-11-23 CN CN202180093881.4A patent/CN116963758A/zh active Pending
- 2021-11-23 AU AU2021403339A patent/AU2021403339A1/en active Pending
- 2021-11-23 US US18/268,118 patent/US20240082392A1/en active Pending
- 2021-11-23 BR BR112023011605A patent/BR112023011605A2/pt unknown
- 2021-11-23 JP JP2023536436A patent/JP2023554401A/ja active Pending
- 2021-11-23 CA CA3201752A patent/CA3201752A1/en active Pending
- 2021-11-23 MX MX2023007293A patent/MX2023007293A/es unknown
- 2021-11-23 EP EP21865362.4A patent/EP4265268A2/en active Pending
- 2021-11-23 WO PCT/CU2021/050013 patent/WO2022127945A2/es active Application Filing
- 2021-11-23 KR KR1020237023660A patent/KR20230122063A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023554401A (ja) | 2023-12-27 |
AU2021403339A1 (en) | 2023-07-06 |
CN116963758A (zh) | 2023-10-27 |
BR112023011605A2 (pt) | 2023-10-31 |
MX2023007293A (es) | 2023-07-04 |
KR20230122063A (ko) | 2023-08-22 |
WO2022127945A3 (es) | 2022-12-22 |
WO2022127945A2 (es) | 2022-06-23 |
CA3201752A1 (en) | 2022-06-23 |
EP4265268A2 (en) | 2023-10-25 |
US20240082392A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002134A1 (es) | Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas. | |
PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
PE20181800A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de mama y otros tipos de cancer | |
PE20181799A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer microcitico de pulmon y otros tipos de cancer | |
CL2017001819A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
ES2722799T3 (es) | Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13 | |
CO2021017845A2 (es) | Proteínas multiespecíficas | |
AR099068A1 (es) | Anticuerpo anti-netrina-1 | |
MX2016002937A (es) | Vacuna oncologica. | |
ES2616258T3 (es) | Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna | |
CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
MX2020010701A (es) | Péptidos antigénicos para la prevención y el tratamiento del cáncer. | |
CU20170112A7 (es) | Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium | |
RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
MY193807A (en) | T-cell receptor and uses thereof | |
PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
AR095386A1 (es) | Péptidos de kntc2 y vacunas que los contienen | |
CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
BR112021023957A2 (pt) | Peptídeos | |
PE20190628A1 (es) | Nuevos peptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cancer | |
CU20200103A7 (es) | Péptido sintético para la inducción de inmunidad antitumoral y antiviral | |
NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
IN2014CH00386A (es) | ||
AR098615A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
RU2010126154A (ru) | Эпитопные пептиды stat3 |